At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Regorafenibdrug
Likely dose
Regorafenib 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Apr 16, 2014·Updated Oct 12, 2021
In Brief
A Phase 2 clinical trial evaluating Regorafenib for Cancer of the Bile Duct. Completed, enrolled 39 participants across 3 sites.
Detailed Summary
The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of the Bile Duct
CountriesUnited States
CollaboratorsBayer
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJun 2014
Primary CompletionDec 2018
Study CompletionSep 2021
TodayJul 2026
First PostedApr 16, 2014
Enrollment StartJun 5, 2014
Primary CompletionDec 10, 2018
Study CompletionSep 20, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 12.2 years ago
Interventions
Regorafenibdrug
Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.